Therasis Secures $12M in Series A Financing

Therasis, Inc., a New York-based oncology drug discovery company, has secured $12m in a Series A financing from Tilocor Life Science.
The funds will be used to launch and further develop its proprietary oncology drug discovery engine, the Therasis Filter™.
Commenting on the funding, Andrea Califano, Ph.D., co-founder of Therasis, was reported as saying: “This funding allows Therasis to build internal capacity and offer potential partners the unprecedented advantages of our screening technology, which greatly facilitates the identification of both disease-relevant activity as well as effective drug combinations”.

Join the discussion